Pancreatic Cancer Drug Doubles Survival, Finally Tackling the Undruggable KRAS Target

The KRAS Door Finally Opens

For over forty years, the scientific community knew exactly what was killing people with pancreatic cancer. More than 90 percent of patients carry mutations in a protein called KRAS. It tells cells to keep dividing, never stop, and the cancer grows relentlessly. Researchers also knew they could not stop it.

Drug molecules typically work by slipping into a crevice on a protein’s surface, like a key finding a lock. KRAS offered no such opportunity. Its surface was smooth, almost frictionless. Scientists began calling it a greasy ball — something you could identify but never grab. The target was declared undruggable, and pancreatic cancer became one of oncology’s most stubborn battles.

That may be changing now.

A drug called daraxonrasib, currently under development in the United States, has produced results that were unthinkable even two years ago. In a large clinical trial involving 500 patients with metastatic pancreatic ductal adenocarcinoma, daraxonrasib extended median survival from 6.7 months to 13.2 months. That is nearly double. Progression-free survival — the period during which the cancer stays contained — also roughly doubled.

The data came from patients who had already failed conventional chemotherapy. By definition, these are people with few options left. The fact that a drug could meaningfully extend life in that setting is what moved some physicians to tears, according to reports. Satarupa Das, a molecular pharmacologist at MIT and co-founder of the company behind the drug, described the moment the results landed as emotionally overwhelming for the entire team.

Why This Matters Beyond the Numbers

A jump from 6.7 months to 13.2 months does not look dramatic on paper. But pancreatic cancer behaves differently than most malignancies. It is rarely caught early. Symptoms like jaundice, severe pain, or unexplained weight loss typically appear only after the disease has already spread. By diagnosis, most patients are already beyond surgical intervention.

That is why any therapy that can buy additional months of controlled life carries disproportionate weight in this disease. Patients are not simply living longer — they are living longer with less progression, less pain, and better quality of life. The trial confirmed measurable improvements across those dimensions.

What makes daraxonrasib fundamentally different from earlier KRAS drugs is how it engages the target. Prior KRAS inhibitors targeted only a single mutation variant, G12C, which accounts for roughly one to three percent of pancreatic cancers. They left the vast majority of patients untouched. Lung cancer patients with that specific mutation did see meaningful benefits from earlier KRAS drugs, but pancreatic cancer patients were largely excluded from those advances.

Daraxonrasib appears to engage multiple KRAS mutation subtypes commonly found in pancreatic tumors. More importantly, it seems capable of binding to the active state of KRAS — the very shape the protein takes when it is driving cancer growth. This is the mechanism that made the target feel unreachable. If the data hold up, daraxonrasib has found a way to grip the smooth surface that had eluded researchers for decades.

The broader implication is significant. Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2030, overtaking colorectal cancer. Every incremental advance against KRAS-driven tumors reverberates far beyond the handful of patients in any single trial. A validated approach to targeting this protein could accelerate strategies across multiple cancer types, including lung and colorectal cancers, where KRAS mutations also play a central role.

The Steve Jobs Connection

The news carries a particularly sharp resonance because so many people first learned about pancreatic cancer through Steve Jobs. When the Apple co-founder died in 2011, the media coverage hammered home how fast and unforgiving the disease could be.

There is an important nuance here that gets lost in retelling. Jobs did not die from the common form of pancreatic cancer that daraxonrasib targets. He had a rare subtype called pancreatic neuroendocrine tumor, or pNET. Those tumors grow more slowly, and Jobs survived for about eight years after diagnosis — a survival story almost certainly impossible under today’s standard treatments for pancreatic ductal adenocarcinoma.

Still, Jobs’s death shaped public understanding of pancreatic cancer as a near-automatic death sentence. That perception is what makes a therapy that doubles survival feel like more than a clinical milestone. It is a shift in the cultural narrative around a disease that has long defined hopelessness in oncology.

Satarupa Das has spoken publicly about her own motivation. Her mother-in-law died of pancreatic cancer in 2018, and the experience drove her to pursue KRAS inhibition with a persistence that many in the field found unusual. Das was a postdoctoral researcher at the time with no industry connections and no track record of drug development. She persisted, eventually securing funding and launching VenatoRx, the company developing daraxonrasib. Her story underscores a recurring pattern in oncology breakthroughs: the people most personally affected by a disease often become its most relentless advocates.

What Comes Next

Several questions remain open. Daraxonrasib will not work for every patient. Some will show no response. Resistance is likely to develop over time, as it does with nearly every targeted therapy. Side effects need to be fully characterized in later-phase trials. The data presented so far come from a phase that likely preceded regulatory submission, and the path to approval still involves uncertainty.

The trial also tested daraxonrasib against conventional chemotherapy, not against the next generation of KRAS-targeted therapies that are themselves advancing. Head-to-head comparisons will matter as the pipeline matures. Several competitors are pursuing similar approaches, and the first drug to reach market could set the standard — or be displaced by a superior molecule.

There is also the question of accessibility. New oncology therapies tend to carry steep price tags in their first years. Whether daraxonrasib becomes broadly available to the patients who need it most will depend on pricing negotiations, insurance coverage, and the priorities of healthcare systems. The history of targeted cancer drugs suggests that even the most effective therapies can take years to reach the people who benefit from them most.

Still, the directional signal is clear. A target declared undruggable for more than four decades is now being approached by a molecule that appears to bind where none could before. If daraxonrasib reaches patients, it will not cure pancreatic cancer. But it will change what is considered possible.

For a disease that has offered almost nothing to its patients in recent decades, that is not a small thing. The next phase of trials will determine whether this opening holds — and whether the rest of oncology gets to walk through it.